Oncodesign Precision Medicine (FRA:ZR8) FCF Margin %: 0.00% (As of Dec. 2025)


FRA:ZR8 Oncodesign Precision Medicine SA FRA:ZR8
32 GF Score
Price €0.30
GF Value €0.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine FCF Margin %?

Oncodesign Precision Medicine FRA:ZR8 32 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates FRA:ZR8 with a GF Score™ of 32/100 and a GF Value™ of €0.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 950 Biotechnology companies, Oncodesign Precision Medicine ranks worse than 105263.05% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oncodesign Precision Medicine's Free Cash Flow for the six months ended in Dec. 2025 was €0.00 Mil. Oncodesign Precision Medicine's Revenue for the six months ended in Dec. 2025 was €0.12 Mil. Therefore, Oncodesign Precision Medicine's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Oncodesign Precision Medicine's current FCF Yield % is 0.00%.

The historical rank and industry rank for Oncodesign Precision Medicine's FCF Margin % or its related term are showing as below:


FRA:ZR8's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.535
* Ranked among companies with meaningful FCF Margin % only.

Oncodesign Precision Medicine FCF Margin % Related Terms

Oncodesign Precision Medicine FCF Margin % Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine FCF Margin % Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:ZR8 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Oncodesign Precision Medicine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's FCF Margin % falls into.


FRA:ZR8
32GF Score
Oncodesign Precision Medicine SA FRA:ZR8
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oncodesign Precision Medicine's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0/0.261
=0.00 %

Oncodesign Precision Medicine's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0.119
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Oncodesign Precision Medicine (FRA:ZR8) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oncodesign Precision Medicine and its competitors. According to the industry distribution chart, Oncodesign Precision Medicine ranks #999999 out of 950 companies in the Biotechnology industry.
Is Oncodesign Precision Medicine's FCF Margin % too high?
Oncodesign Precision Medicine's current FCF Margin % is 0.00%. Based on the distribution chart, Oncodesign Precision Medicine ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 32/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #999999 out of 950 companies for FCF Margin %. This places Oncodesign Precision Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current FCF Margin % is 0.00%. Oncodesign Precision Medicine's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for FRA:ZR8:

  • FCF Margin %: 0.00%
  • GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ALOPM:France
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score

Get the complete analysis for FRA:ZR8

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.26
GF Value